Caresyntax has secured $180 million in a Series C extension and debt financing round to advance its surgical intelligence platform. This SaaS platform aims to improve patient surgery outcomes by integrating technology across the entire surgical process, from booking staff to monitoring surgeries with video and providing analytics on outcomes and costs. The platform can also connect with existing robotic surgery tools worldwide.
This new funding, which includes $80 million in equity and $100 million in growth debt from investors like Symbiotic Capital, BlackRock Innovation Capital, and Optum Ventures, brings Caresyntax’s total funding to around $400 million since its inception in 2013. The funds will be used to boost customer adoption in the U.S. and EMEA regions, accelerate AI development, and support acquisitions.
Caresyntax has seen a 75% revenue increase in the first half of 2024, driven by its comprehensive data acquisition strategy, which gathers both structured and unstructured data during the care pathway. The company’s technology is currently deployed in over 7,000 operating rooms and used by more than 40,000 surgical teams worldwide.
